Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis

Infection and Immunity

Volumn 82, Issue 3, 2014, Pages 1030-1035

  Ferreira, Maria Carolina ^a,b   Whibley, Natasha ^a   Mamo, Anna J ^a   Siebenlist, Ulrich ^c   Chan, Yvonne R ^a   Gaffen, Sarah L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE-PHASE PROTEINS; ANIMALS; CANDIDA ALBICANS; CANDIDIASIS, ORAL; INTERLEUKIN-17; LIPOCALINS; MICE; MICE, INBRED C57BL; MOUTH MUCOSA; MUCOUS MEMBRANE; ONCOGENE PROTEINS; RECEPTORS, INTERLEUKIN-17; UP-REGULATION;

EID: 84894285479     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01389-13     Document Type: Article

References (40)

1. Fidel PL, Jr. 2011. Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis. Adv. Dent. Res. 23:45-49. http://dx.doi .org/10.1177/0022034511399284.
2. Glocker E, Grimbacher B. 2010. Chronic mucocutaneous candidiasis and congenital susceptibility to Candida. Curr. Opin. Allergy Clin. Immunol. 10:542-550. http://dx.doi.org/10.1097/ACI.0b013e32833fd74f.
3. Huppler AR, Bishu S, Gaffen SL. 2012. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res. Ther. 14:217. http://dx.doi.org/10.1186/ar3893.
4. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC.2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4:165rv13. http://dx.doi.org/10.1126/scitranslmed.3004404.
5. Cassone A. 2013. Development of vaccines for Candida albicans: fighting a skilled transformer. Nat. Rev. Microbiol. 11:884-891. http://dx.doi.org /10.1038/nrmicro3156.
6. Milner J, Holland S. 2013. The cup runneth over: lessons from the everexpanding pool of primary immunodeficiency diseases. Nat. Rev. Immunol. 13:635-648. http://dx.doi.org/10.1038/nri3493.
7. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung JW, Filler SG, Masso-Welch P, Edgerton M, Gaffen SL. 2009. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206:299-311. http://dx.doi.org/10.1084/jem.20081463.
8. Ho AW, Shen F, Conti HR, Patel N, Childs EE, Peterson AC, Hernandez-Santos N, Kolls JK, Kane LP, Ouyang W, Gaffen SL. 2010. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J. Immunol. 185:1063-1070. http://dx.doi .org/10.4049/jimmunol.0903739.
9. Farah CS, Hu Y, Riminton S, Ashman RB. 2006. Distinct roles for interleukin-12p40 and tumour necrosis factor in resistance to oral candidiasis defined by gene targeting. Oral Microbiol. Immunol. 21:252-255. http://dx.doi.org/10.1111/j.1399-302X.2006.00288.x.
10. Puel A, Cypowji S, Bustamante J, Wright J, Liu L, Lim H, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman N, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova J-L. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:65-68. http://dx.doi.org/10.1126 /science.1200439.
11. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, Ouachee-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougneres PF, Kumararatne D, Marodi L, Nahum A, Roifman C, Blanche S, Fischer A, Bodemer C, Abel L, Lilic D, Casanova JL. 2010. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207:291-297. http://dx.doi .org/10.1084/jem.20091983.
12. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Strobel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N, Meager A. 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207:299-308. http://dx.doi.org/10.1084 /jem.20091669.
13. Gaffen SL. 2009. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9:556-567. http://dx.doi.org/10.1038/nri2586.
14. Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, Rybojad M, Belkadi A, Picard C, Abel L, Fieschi C, Puel A, Li X, Casanova J-L. 2013. A biallelic ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39:676-686. http://dx.doi.org/10.1016/j.immuni.2013.09.002.
15. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199. http://dx.doi.org/10.1056/NEJMoa1109997.
16. Patel DD, Lee DM, Kolbinger F, Antoni C. 2013. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72(Suppl 2):iii116-iii123. http://dx.doi.org/10.1136/annrheumdis-2012-202371.
17. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366:1181-1189. http://dx.doi.org/10.1056/NEJMoa1109017.
18. Miossec P, Kolls JK. 2012. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11:763-776. http://dx.doi.org/10 .1038/nrd3794.
19. Ford AC, Peyrin-Biroulet L. 2013. Opportunistic infections with antitumor necrosis factor-alpha therapy in inflammatory bowel disease: metaanalysis of randomized controlled trials. Am. J. Gastroenterol. 108:1268-1276. http://dx.doi.org/10.1038/ajg.2013.138.
20. Shen F, Ruddy MJ, Plamondon P, Gaffen SL. 2005. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17-and TNF-α-induced genes in bone cells. J. Leukoc. Biol. 77:388-399. http://dx .doi.org/10.1189/jlb.0904490.
21. Shen F, Hu Z, Goswami J, Gaffen SL. 2006. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281:24138-24148. http://dx.doi.org/10.1074/jbc.M604597200.
22. Karlsen JR, Borregaard N, Cowland JB. 2010. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IκB-ζ but neither by C/EBP-β nor C/EBP-δ. J. Biol. Chem. 285:14088-14100. http://dx .doi.org/10.1074/jbc.M109.017129.
23. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J. 2002. An iron delivery pathway mediated by a lipocalin. Mol. Cell 10:1045-1056. http://dx.doi .org/10.1016/S1097-2765(02)00710-4.
24. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. 2002. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 10: 1033-1043. http://dx.doi.org/10.1016/S1097-2765(02)00708-6.
25. Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, Mak TW, Clifton MC, Strong RK, Ray P, Kolls JK. 2009. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J. Immunol. 182:4947-4956. http://dx.doi.org/10.4049/jimmunol.0803282.
26. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. 2004. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432:917-921. http://dx.doi.org/10.1038/nature03104.
27. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW. 2006. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemiareperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 103:1834-1839. http: //dx.doi.org/10.1073/pnas.0510847103.
28. Claudio E, Sonder SU, Saret S, Carvalho G, Ramalingam TR, Wynn TA, Chariot A, Garcia-Perganeda A, Leonardi A, Paun A, Chen A, Ren NY, Wang H, Siebenlist U. 2009. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J. Immunol. 182:1617-1630. http://www.jimmunol.org/content/182/3/1617.long.
29. Solis NV, Filler SG. 2012. Mouse model of oropharyngeal candidiasis. Nat. Protoc. 7:637-642. http://dx.doi.org/10.1038/nprot.2012.011.
30. Hernández-Santos N, Gaffen SL. 2012. Th17 cells in immunity to Candida albicans. Cell Host Microbe 11:425-435. http://dx.doi.org/10.1016/j .chom.2012.04.008.
31. Puel A, Picard C, Cypowyj S, Lilic D, Abel L, Casanova JL. 2010. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr. Opin. Immunol. 22:467-474. http://dx.doi.org /10.1016/j.coi.2010.06.009.
32. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639-646. http://dx.doi.org/10.1038/ni1467.
33. Devireddy LR, Gazin C, Zhu X, Green MR. 2005. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123:1293-1305. http://dx.doi.org/10.1016/j.cell.2005.10.027.
34. Devireddy LR, Teodoro JG, Richard FA, Green MR. 2001. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 293:829-834. http://dx.doi.org/10.1126/science .1061075.
35. Raffatellu M, George MD, Akiyama Y, Hornsby MJ, Nuccio SP, Paixao TA, Butler BP, Chu H, Santos RL, Berger T, Mak TW, Tsolis RM, Bevins CL, Solnick JV, Dandekar S, Baumler AJ. 2009. Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimu-rium for growth and survival in the inflamed intestine. Cell Host Microbe 5:476-486. http://dx.doi.org/10.1016/j.chom.2009.03.011.
36. Liu JZ, Pezeshki M, Raffatellu M. 2009. Th17 cytokines and hostpathogen interactions at the mucosa: dichotomies of help and harm. Cytokine 48:156-160. http://dx.doi.org/10.1016/j.cyto.2009.07.005.
37. Liu Z, Petersen R, Devireddy L. 2013. Impaired neutrophil function in 24p3 null mice contributes to enhanced susceptibility to bacterial infections. J. Immunol. 190:4692-4706. http://dx.doi.org/10.4049/jimmunol .1202411.
38. Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK. 2005. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure 13: 29-41. http://dx.doi.org/10.1016/j.str.2004.10.009.
39. Guglani L, Gopal R, Rangel-Moreno J, Junecko BF, Lin Y, Berger T, Mak TW, Alcorn JF, Randall TD, Reinhart TA, Chan YR, Khader SA.2012. Lipocalin 2 regulates inflammation during pulmonary mycobacterial infections. PLoS One 7:e50052. http://dx.doi.org/10.1371/journal .pone.0050052.
40. Hu CJ, Bai C, Zheng XD, Wang YM, Wang Y. 2002. Characterization and functional analysis of the siderophore-iron transporter CaArn1p in Candida albicans. J. Biol. Chem. 277:30598-30605. http://dx.doi.org/10 .1074/jbc.M204545200.